The CNAP Artemisia Research Project is funded by The Bill & Melinda Gates Foundation. In 2006 the project received a grant of $13.6 million. This was followed by a second grant of $12.49 million in 2009 to support late-stage development of high-yielding varieties and their delivery to Artemisia producers in Africa and Asia. The project builds on work financed by the Medicines for Malaria Venture and GlaxoSmithKline, and supported by core-funding to CNAP from the Garfield Weston Foundation.

Two solutions which complement plant-based production of artemisinin are also under development

1) A new synthetic drug, known as Oz277 or RBx11160, which is based on the trioxane ring system of artemisinin. This is currently being developed by the Indian manufacturer of generic dugs, Ranbaxy, in partnership with the not for profit public private partnership, Medicines for Malaria Venture (MMV)

2) The manufacture of artemisinin through fermentation, which is under development by a consortium led by the Institute for One World Health

It is anticipated that synthetic alternatives, fermentation and high yield A. annua will all be needed to secure supply and reduce the cost of artemisinin.